In solid tumors, HER2-positive breast cancer remains the most common target of ADCs, followed by other HER2-expressing tumors such as non-small cell lung cancer (NSCLC) and urothelial carcinoma [96]. Here, ERBB2 is linked to urothelial carcinoma.